Publications
Probity Medical Research has compiled journals, articles and presentations for your personal review. Please use the search features below to find an article.
If you would like to request an article for personal review please complete the registration form. These publications are for personal use only and cannot be distributed.
Already granted access to an article?
If you cannot find the article you are looking for please contact Probity Medical Research.
Journals, Articles and Presentations
Articles by Publication Year
What’s Your Diagnosis? Tender Honey-Colored Lesion With “Stuck-on” Crust
Consultant for Pediatricians 2013 Feb;12(2):83-85.
Five Things to Know About Psoriasis
Canadian Medical Association Journal. 2013 Feb 19;185(3):E174. doi: 10.1503/cmaj.090631. Epub 2012 Sep 4.
Examining the Risk of Cardiovascular Disease in Patients with Psoriasis: A Critical Review
Journal of Cutaneous Medicine and Surgery 2013 Mar-Apr;17(2):89-105.
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Psoriasis: 16-Week Results of a Phase 3, Randomized, Controlled Trial (ESTEEM 1)
Presented at the 47th Congress of the German Society of Dermatology, May 1-4, 2013
Tofacitinib has no clinically significant effects in cells controlling chronic viral infection and reactivation
Presented at the International Investigative Dermatology (IID), Edinburgh, Scotland, United Kingdom, May 8-11, 2013
Understanding and Assessing Potential Serious Adverse Events: A Practical Approach to Understanding the Benefits and Harm of Psoriasis Treatments
Journal of Cutaneous Medicine and Surgery 2013 May-Jun;17(3):189-196.
Dose-Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e44; doi:10.1038/psp.2013.22; advance online publication 22 May 2013
Tofacitinib ointment efficacy and biomarker improvement in psoriasis
Presented at International Investigative Dermatology (IID), Edinburgh, Scotland, United Kingdom, May 8-11, 2013
Secukinumab effectively treats moderate-to-severe plaque psoriasis in a subset of patients able to maintain a response for as long as 24 weeks after cessation of therapy: Results of a dose finding study
Presented at Canadian Dermatology Association (CDA) 88th Annual Conference, Quebec City, Quebec, Canada, Jun 27-30, 2013
Safety of Ustekinumab From the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
Presented at EULAR Annual European Congress of Rheumatology, Madrid, Spain, Jun 12-15, 2013
About PMR | Investigators | Experience | Locations | News | Publications | Privacy Policy | Contact | Sitemap |
Copyright 2014 Probity Medical Research Inc. All Rights Reserved.